Superworth

Kiniksa Pharmaceuticals International KNSA

Drug Manufacturers - General, Healthcare
$90.80
−1.56%
Market cap
$7.1B
PE
93.6×
3y median 87.6×
Forward PE
n/m
not a meaningful number
Price to sales
8.4×
EV/EBIT
65.5×
Revenue, 12 months
$840.8M
+59% on a year ago
Net margin
9.6%
Free cash flow yield
2.6%

Kiniksa Pharmaceuticals International trades at 93.6× trailing earnings, near its ten-year median. Revenue was $840.8M over the last twelve months, up 59% on a year earlier with a 10% net margin.

Charts

Financials

Income statement for KNSA, by quarter
Income statementQ3 FY23Q4 FY23Q1 FY24Q2 FY24Q3 FY24Q4 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26
$67M−32%$83.4M+35%$79.9M+65%$108.6M+52%$112.2M+67%$122.5M+47%$137.8M+73%$156.8M+44%$180.9M+61%$202.1M+65%$214.3M+56%$243.6M+55%
Cost of revenue$9.1M+31%$66.1M+115%$10.6M+50%$12.3M+60%$20.1M+121%$17.9M−73%$17.9M+69%$18.6M+51%$20.3M+1%$20.9M+17%$20.8M+16%$23.6M+27%
Gross profit$58M−37%$17.3M−44%$69.3M+68%$96.3M+51%$92.1M+59%$104.6M+505%$119.9M+73%$138.2M+44%$160.6M+74%$181.2M+73%$193.5M+61%$220M+59%
R&D$17.1M+4%$20.1M+39%$26.3M+74%$24M+1%$26.1M+52%$35.2M+76%$19.3M−27%$18.8M−22%$24.2M−7%$34.6M−2%$27.5M+42%$40.9M+118%
SG&A$34.5M+40%$36.7M+35%$38.7M+33%$42.4M+45%$46.4M+35%$40.5M+10%$43.5M+13%$46.9M+11%$49.1M+6%$56.8M+40%$61.2M+41%$63.9M+36%
−$10.9M$81K−99%−$16.5M+48%−$117K−96%−$9.7M−12%−$19.3M$13.3M$20.2M$24M$19.8M$29.3M+121%$27.2M+35%
Pre-tax income−$8.5M$2.5M−64%−$14.3M+53%$2.3M−$7.2M−15%−$17M$15.6M$22.9M+893%$27.2M$23.3M$32.7M+110%$31.1M+36%
$5.4M−$22.8M$3.4M+18%$6.2M$5.5M+3%−$8.1M−65%$7M+105%$5M−19%$8.7M+59%$9.1M$10.1M+44%$5.7M+13%
Net income−$13.9M$25.2M+466%−$17.7M+44%−$3.9M−$12.7M−8%−$8.9M$8.5M$17.8M$18.4M$14.2M$22.6M+165%$25.4M+43%
−$0.20$0.35+483%−$0.25+39%−$0.06−$0.18−10%−$0.12$0.11$0.23$0.23$0.17$0.27+146%$0.30+30%
70.2M−1%72.2M+2%70.6M+1%71M−1%71.7M+2%72.3M+0%76.1M+8%77.9M+10%80M+12%81.8M+13%82.4M+8%83.4M+7%

Gross profit: 21 periods, Q2 FY21 to Q2 FY26: not printed by the filing, worked out from its own lines.

R&D: Q1 FY17: 6 months less the 3 months printed beside them.

SG&A: Q1 FY17: 6 months less the 3 months printed beside them.

Operating income: Q1 FY17 and Q1 FY18: 6 months less the 3 months printed beside them.

Pre-tax income: Q1 FY17 and Q1 FY18: 6 months less the 3 months printed beside them.

Income tax: Q1 FY17 and Q1 FY18: 6 months less the 3 months printed beside them.

Net income: Q1 FY17 and Q1 FY18: 6 months less the 3 months printed beside them.

EPS, diluted: 10 periods, Q1 FY17 to Q4 FY25: quarter's net income to common over its shares, to the cent.

Diluted shares: Q1 FY17: share-days: the 6-month average less the second quarter's. 6 periods, Q4 FY17 to Q4 FY24: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. Q4 FY22 and Q4 FY25: share-days: the 12-month average less the 9-month, weighted by days. Q4 FY23: the earlier year to date counted no dilution: the quarter's basic count plus the later year to date's dilution.

From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.

Peers

Companies in Drug Manufacturers - General nearest Kiniksa Pharmaceuticals International's size, closest first.

CompanyMarket capPEIts 10y median PEFwd PEP/SRevenue growthNet margin
KNSAKiniksa Pharmaceuticals International$7.1B93.6×87.6×8.4×+59%9.6%
ALKSAlkermes plc.$7.5B118×16.0×4.5×+11%4.0%
AMRXAmneal Pharmaceuticals$6.5B41.7×51.4×2.1×+9%5.0%
LGNDLigand Pharmaceuticals$6.1B32.7×37.6×21.1×+55%67.9%
CORTCorcept Therapeutics$8.7B192×28.3×10.5×+16%6.6%
PTGXProtagonist Therapeutics$9B135×60.1×32.0×+35%29.4%
TGTXTG Therapeutics$9.2B21.9×19.6×11.5×+76%55.2%
BMRNBiomarin Pharmaceutical$11.1B155×72.5×3.3×+11%2.1%
INDVIndivior Pharmaceuticals$4.3B10.2×19.9×3.1×+16%32.8%
ARQTArcutis Biotherapeutics$3.9B142×117×8.5×+76%6.1%
LQDALiquidia$3.7B30.1×49.4×8.3×n/m30.7%
Peer median$7B79.9×43.5×8.4×+16%18.0%

More on Kiniksa Pharmaceuticals International

Each number over time

Its groups

About

Industry
Drug Manufacturers - General
Sector
Healthcare

Valuation data, not investment advice. Prices as of .